newsfilter
← Latest News
Business Wire·

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. AngioDynamics, Inc.